A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver metastases; Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 24 Sep 2024 Status changed from active, no longer recruiting to completed.
- 21 Mar 2024 Planned End Date changed from 3 Dec 2023 to 31 Jul 2024.
- 17 May 2022 Planned End Date changed from 30 Apr 2022 to 3 Dec 2023.